Who it is for
Adults whose clinician prescribed Egrifta SV or Egrifta WR and who need the labeled daily amount for that exact product.
US prescription label · Egrifta
Tesamorelin Dosage Calculator
Look up the FDA-labeled daily tesamorelin dose for Egrifta SV or Egrifta WR. The approved use is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The two products are not substitutable.
Labeled doses
- Egrifta SV — 1.4 mg once daily
- Egrifta WR — 1.28 mg once daily
- Not based on body weight
- Not a weight-loss or research-vial calculator
Prescribed product
Select the name on the US carton. Egrifta SV and Egrifta WR are not substitutable, and the labeled adult dose does not change with body weight.
Labeled US dose
The figure below is the daily dose in that product's prescribing information. Preparation and storage stay in the Instructions for Use for that kit.
Press Show labeled dose. Egrifta SV starts at 1.4 mg once daily. Egrifta WR is 1.28 mg once daily.
What is a tesamorelin dosage calculator?
A tesamorelin dosage calculator for the United States shows the FDA-labeled daily dose of the Egrifta product on the prescription. Tesamorelin is a growth hormone-releasing factor analog. The approved use is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
The labeled amount is not based on body weight. This page does not adjust a dose, compare research vials, or replace the prescriber, pharmacist, or the Instructions for Use in the box.
What it shows
The once-daily dose and the labeled injection volume from that product's prescribing information.
What the label excludes
Weight-loss management. Long-term cardiovascular safety has not been established.
Why the product name matters
Egrifta SV and Egrifta WR use different vial strengths and different daily doses. The FDA says they are not substitutable.
How to use this tesamorelin dosage calculator
Match the calculator to the carton, then read that product's own instructions for mixing and storage.
- Read the cartonChoose Egrifta SV (2 mg vial) or Egrifta WR (11.6 mg vial). An older 1 mg Egrifta carton has its own label and is not listed here.
- Show the labeled doseSV is 1.4 mg once daily. WR is 1.28 mg once daily. Do not copy one product's number onto the other.
- Use the kit instructionsDiluent, mixing, and how long a vial may be kept are printed in the Instructions for Use for that product only.
- Ask the prescriber if anything differsThis page cannot clear contraindications, check IGF-1, or change a prescription.
Labeled US doses
Both products are injected subcutaneously once daily. The milligram dose and the labeled volume are different.
| Product | Vial | Daily dose | Labeled volume |
|---|---|---|---|
| Egrifta SV | 2 mg | 1.4 mg | 0.35 mL |
| Egrifta WR | 11.6 mg | 1.28 mg | 0.16 mL |
Accuracy of the results
Doses are taken from the US prescribing information published on DailyMed for Egrifta. Egrifta WR labeling revised March 2025 lists 1.28 mg (0.16 mL) once daily and states it is not substitutable with Egrifta SV. Egrifta SV labeling lists 1.4 mg (0.35 mL) once daily for the 2 mg vial.
What it matches
- The adult labeled dose for SV and for WR
- The labeled volume of reconstituted solution
- The rule that the two products are not interchangeable
What stays with the clinician
- Whether tesamorelin should be started or stopped
- Glucose, IGF-1, malignancy history, and pregnancy
- Mixing, storage, and injection steps in the kit
- Any carton other than SV 2 mg or WR 11.6 mg
Tesamorelin dosage calculator FAQs
Common questions about the US labeled tesamorelin dose.
What is a tesamorelin dosage calculator?
In the United States, a tesamorelin dosage calculator looks up the FDA-labeled daily dose for the Egrifta product a prescriber selected. Tesamorelin is a growth hormone-releasing factor analog. The approved use is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The labeled dose does not change with body weight. This page is not a personal prescription, and it does not calculate research-vial or bodybuilding doses.
What is the US labeled dose?
Egrifta SV, the 2 mg vial, is labeled 1.4 mg (0.35 mL of the reconstituted solution) subcutaneously once daily. Egrifta WR, the 11.6 mg vial, is labeled 1.28 mg (0.16 mL) subcutaneously once daily. The FDA says these products are not substitutable. Each label applies only to that vial strength. Use the Instructions for Use that came with the box you were given.
Does the dose depend on weight?
No. The prescribing information sets one adult daily dose for each product. It does not use body weight, sex, or a fat-loss goal to raise or lower the amount. Unofficial calculators that suggest a dose from weight are not the FDA label. If a clinician changes therapy, that decision belongs to them, not to a website formula.
Can this be used for weight loss?
The label says tesamorelin is not indicated for weight loss management. Long-term cardiovascular safety has not been established. It is also not approved for bodybuilding, anti-aging, or general fat loss. This tool only repeats the labeled dose for the approved HIV-associated lipodystrophy use. It will not suggest another amount.
Are Egrifta SV and Egrifta WR the same?
Both contain tesamorelin, but the vial strength, daily dose, diluent, and how long a vial lasts are different. The WR prescribing information states the two products are not substitutable. A dose or volume from one label must not be used for the other product. Confirm the name printed on the carton before you rely on a number from this page.
Is this medical advice?
No. It is an educational reading of the public US prescribing information. It does not decide whether tesamorelin is appropriate for any person. The label lists contraindications, including pregnancy, active malignancy, and disruption of the hypothalamic-pituitary axis, plus warnings about IGF-1, fluid retention, and glucose. Read the full label and talk with the prescriber and pharmacist.